Status unknownNCT00935246Updated Dec 31, 2015

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

An interventional study of Escitalopram in Depression, Continuous Antidepressant Abuse and Adverse Reaction to Drug, sponsored by Samsung Medical Center. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 89 Years. Per ClinicalTrials.gov, last updated 2015-12-31.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2015), so the status shown — last known as Active, not recruiting — may be out of date.

Phase: Not applicable
Study type: Interventional
Enrollment: 202
Allocation: Non-randomized
Ages: 19 Years to 89 Years
Sex: All

Study summary

To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).

Read the detailed description

The purposes of this study are:

To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning)
To improve the success rate of escitalopram treatment response for depressed patients

Conditions studied

Depression
Continuous Antidepressant Abuse
Adverse Reaction to Drug

Browse trials for

Drug-Related Side Effects and Adverse Reactions 437

Keywords

Genomic devices
Prediction of Escitalopram Response
Depressed Patients

In context

Drug-Related Side Effects and Adverse Reactions

437 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 76 are open to participants now.

This study's planned enrollment of 202 is above the median of 103 across 255 interventional studies indexed under Drug-Related Side Effects and Adverse Reactions.

Lead sponsor

Samsung Medical Center is the lead sponsor of 980 studies on the registry; 146 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 19 Years to 89 Years
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.
interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians

Exclusion criteria

Exclusion Criteria:

received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

Study design

Phase: Not applicable
Primary purpose: Treatment
Allocation: Non-randomized
Intervention model: Parallel assignment
Masking: Triple (Participant, Investigator, Outcomes assessor)
Enrollment: 202 participants (estimated)

Study arms

Experimental
Antidepressant treated group
Antidepressant treated group: depressed patients treated with Escitalopram
Drug: Escitalopram
No intervention
other antidepressant treated group
other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram

Interventions

DrugEscitalopram
Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
Also known as: Escitalopram : Lexapro

What researchers measure

Primary outcomes

antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks
Time frame: 8 weeks

Secondary outcomes

biological value at 0 week and 8 weeks
Time frame: 8 weeks

Study locations

1 site

Samsung Medical Center
Kangnam, Seoul 135-710, Korea, Republic of

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Dec 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00935246
Lead sponsor: Samsung Medical Center
Collaborators: H. Lundbeck A/S
Responsible party: Doh Kwan Kim (M.D., Ph.D., Samsung Medical Center) — Principal investigator
First posted: Jul 8, 2009
Start date: Dec 2008
Primary completion: Oct 2011
Completion: Dec 2016 (estimated)
Last update: Dec 31, 2015

Study contacts

Doh Kwan Kim, PhD, M.D.

principal investigator · Samsung Medical Center

Oversight

Data monitoring committee: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Other studies from this sponsor

Samsung Medical Center

Start the discussion